IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
S.F. Holding 06936.HK	Air Freight & Logistics	34.3	200	7,333	2024/11/22	2024/11/26	2024/11/27
Jiuyuan Gene 02566.HK	Biotechnology - Medical Devices	11.48-12.56	200	2,537	2024/11/25	2024/11/27	2024/11/28
Mokingran 02585.HK	Watch & Jewellery	12-14.4	200	2,909	2024/11/26	2024/11/28	2024/11/29

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

S.F. Holding
06936.HK

Air Freight & Logistics

34.3

200

7,333

2024/11/22

2024/11/26

2024/11/27

Jiuyuan Gene
02566.HK

Biotechnology - Medical Devices

11.48-12.56

200

2,537

2024/11/25

2024/11/27

2024/11/28

Mokingran
02585.HK

Watch & Jewellery

12-14.4

200

2,909

2024/11/26

2024/11/28

2024/11/29

Summary

We are a leader in the bioactive ingredient-based professional skin treatment product industry in China. We design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. We also develop and manufacture rare ginsenosides technology-based functional foods. We utilize proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors. The skin-related beauty sector comprises (i) skin care and treatment, and (ii) skin rejuvenation applications. Further, skin care and treatment includes (i) general skincare, (ii) functional skincare and (iii) medical dressings, with the latter two constituting the professional skin treatment sector. The overall skin care and treatment market in China was very fragmented in 2021. See “– Market Landscape.” According to Frost & Sullivan, our market share was approximately 1.1 % of China’s overall skin care and treatment market in terms of retail sales in 2021. Within this market during the Track Record Period, we primarily focused on the professional skin treatment product market, including functional skincare products and medical dressings. Professional skin treatment products are used to address various skin issues, such as skin sensitivity, premature skin aging, chronic eczema and allergies, and can also be used for general skincare of consumers. China’s overall professional skin treatment product market in terms of retail sales value was RMB56.6 billion in 2021. In addition, certain of our pipeline products target skin rejuvenation applications. Our years of R&D on bioactive ingredients and integrated business model enable us to achieve the technological and market leadership positions in the industry. According to Frost & Sullivan: ‧ We were the second-largest professional skin treatment product company in China in 2021 with a retail sales value of RMB6.0 billion as well as the largest collagen-based professional skin treatment product company by retail sales in China for the latest three consecutive years since 2019; ‧ Collgene (可麗金) and Comfy (可復美), our flagship brands of recombinant collagen-based products, were the third and the fourth best-selling professional skin treatment brands, respectively, with a retail sales value of RMB2.9 billion and RMB2.7 billion, respectively, in China in 2021; ‧ Our proprietary recombinant collagen technology was the first in its field to be awarded a patent in China; and ‧ We are the first company to obtain a medical device registration for recombinant collagen-based product in China. As of the Latest Practicable Date, we had a portfolio of 105 SKUs across eight major brands covering functional skincare, medical dressings and functional foods, namely Comfy, Collgene, Keyu, Kehen, Kefuping, Leeyen, SKIGIN, and Shengan. We have achieved significant growth during the Track Record Period. Our revenue increased from RMB956.7 million in 2019 to RMB1,190.5 million in 2020, and further increased to RMB1,552.5 million in 2021. Our revenue increased from RMB520.6 million for the five months ended May 31, 2021 to RMB723.0 million for the same period in 2022. Moreover, our net profit amounted to RMB575.2 million, RMB826.5 million, RMB828.1 million and RMB313.6 million in 2019, 2020, 2021 and the five months ended May 31, 2022, respectively, with net margin of 60.1%, 69.4%, 53.3% and 43.4% during the same periods. The overall decline in our net margin during the Track Record Period was mainly attributable to the increase in online marketing expenses, resulting from the continuous expansion of our online sales channels as we increased spending on online sales and marketing activities on e-commerce platforms and social media platforms to follow industry trends and capture market opportunities. Our adjusted net profit (non-IFRS measure) amounted to RMB575.2 million, RMB827.1 million, RMB851.3 million and RMB336.1 million in 2019, 2020, 2021 and the five months ended May 31, 2022, respectively, with adjusted net profit margin (non-IFRS measure) of 60.1%, 69.5%, 54.8% and 46.5% during the same periods. Source: Giant Biogene (02367) Prospectus (IPO Date : 2022/10/25)
Listing Market	MAIN
Industry	Beauty & Toiletries Products and Services
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Fan Daidi (57.32%)
Directors	Yan Jianya (Chairman and Chief Executive Officer and Executive Director) Fang Juan (Senior Vice President and Executive Director) Ye Juan (Senior Vice President and Executive Director) Yan Yubo (Executive Director) Zhang Huijuan (Executive Director) Huang Jin (Independent Non-Executive Director) Shan Wenhua (Independent Non-Executive Director) Wong Sze Wing (Independent Non-Executive Director)
Company Secretary	Yan Yubo Yuen Wing Yan, Winnie
Principal Bankers	China Merchants Bank Shanghai Pudong Development Bank Co., Ltd. Chang’an Bank Co., Limited
Solicitors	Clifford Chance Maples and Calder (Hong Kong) LLP
Auditors	Ernst & Young
Registered Office	5th Floor, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong
Share Registrars	Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No	(852) 2980-1333
Internet Address	http://www.xajuzi.com
Email Address	ir@xajuzi.com
Tel No	(86 29) 8115-6502
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates